Peptidase activity on the surface of the porcine buccal mucosa.
Peptide drugs in buccal bioadhesive delivery systems are exposed to the surface of the buccal mucosa at high concentrations over long periods of time. The peptidase activity on the surface of the buccal mucosa has not been evaluated as a barrier to peptide buccal delivery. The in vitro stability of various synthetic substrates on the surface of intact porcine buccal mucosa was determined. No carboxypeptidase or dipeptidyl peptidase IV activity was detected on the buccal mucosa, while aminopeptidase N activity was detected using Leu-p-nitroanilide. No endopeptidase activity was observed towards the peptide substrates. Insulin and insulin B-chain were intact at the 2 h time point at 37 degrees C, while the percent of parent Leu-enkephalin remaining was 18+/-9 (mean+/-S.D., n=9). In the presence of aminopeptidase inhibitors, amastatin, sodium deoxycholate and EDTA, the degradation of Leu-enkephalin was dramatically reduced. This work suggests that the buccal route maybe advantageous for the delivery of peptides that are susceptible to such activities. The inclusion of aminopeptidase inhibitors in buccal bioadhesive delivery systems could improve buccal bioavailability of Leu-enkephalin. We suggest that compared with the existing in vitro metabolism methods, the analysis of peptide or protein metabolism on intact buccal mucosa could better predict the degradation of the drug as it crosses the tissue.
Walker
Greg F
GF
Centre of Pharmacy, Institute of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Althanstr. 14, A-1090 Vienna, Austria. gregthekiwi@hotmail.com
Langoth
Nina
N
Bernkop-Schnürch
Andreas
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D007611:Aprotinin / Q000494:pharmacology; D004743:Enkephalin, Leucine / Q000493:pharmacokinetics; D006868:Hydrolysis / Q000187:drug effects; D007328:Insulin / Q000493:pharmacokinetics; D009061:Mouth Mucosa / Q000201:enzymology*; D010447:Peptide Hydrolases / Q000378:metabolism*; D010455:Peptides; D011480:Protease Inhibitors / Q000494:pharmacology; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology; D013379:Substrate Specificity; D013499:Surface Properties; D013552:Swine
D000900:Anti-Bacterial Agents; D007328:Insulin; D010455:Peptides; D011480:Protease Inhibitors; D015842:Serine Proteinase Inhibitors; D004743:Enkephalin, Leucine; C016977:amastatin; D007611:Aprotinin; D010447:Peptide Hydrolases